JP7115755B2 - 肝損傷の処置における使用のためのマクロファージに基づく治療法 - Google Patents

肝損傷の処置における使用のためのマクロファージに基づく治療法 Download PDF

Info

Publication number
JP7115755B2
JP7115755B2 JP2019515418A JP2019515418A JP7115755B2 JP 7115755 B2 JP7115755 B2 JP 7115755B2 JP 2019515418 A JP2019515418 A JP 2019515418A JP 2019515418 A JP2019515418 A JP 2019515418A JP 7115755 B2 JP7115755 B2 JP 7115755B2
Authority
JP
Japan
Prior art keywords
cells
liver
macrophages
bmdm
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532634A5 (enExample
JP2019532634A (ja
Inventor
フォーブス、ステュアート
スターキー ルイス、フィリップ
フォレスター、レズリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615923.8A external-priority patent/GB201615923D0/en
Priority claimed from GBGB1707183.8A external-priority patent/GB201707183D0/en
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of JP2019532634A publication Critical patent/JP2019532634A/ja
Publication of JP2019532634A5 publication Critical patent/JP2019532634A5/ja
Application granted granted Critical
Publication of JP7115755B2 publication Critical patent/JP7115755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019515418A 2016-09-19 2017-09-18 肝損傷の処置における使用のためのマクロファージに基づく治療法 Active JP7115755B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1615923.8A GB201615923D0 (en) 2016-09-19 2016-09-19 Macrophage-based therapy
GB1615923.8 2016-09-19
GB1707183.8 2017-05-05
GBGB1707183.8A GB201707183D0 (en) 2017-05-05 2017-05-05 Macrophage-based therapy
PCT/GB2017/052769 WO2018051136A1 (en) 2016-09-19 2017-09-18 Macrophage-based therapy for use in the treatment of liver injury

Publications (3)

Publication Number Publication Date
JP2019532634A JP2019532634A (ja) 2019-11-14
JP2019532634A5 JP2019532634A5 (enExample) 2020-11-12
JP7115755B2 true JP7115755B2 (ja) 2022-08-09

Family

ID=60083347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515418A Active JP7115755B2 (ja) 2016-09-19 2017-09-18 肝損傷の処置における使用のためのマクロファージに基づく治療法

Country Status (6)

Country Link
US (1) US11285174B2 (enExample)
EP (2) EP3515460B1 (enExample)
JP (1) JP7115755B2 (enExample)
CN (1) CN109789163A (enExample)
AU (1) AU2017328913B2 (enExample)
WO (1) WO2018051136A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2896548T3 (es) 2015-10-30 2022-02-24 Biolamina Ab Métodos de producción de hepatocitos
GB2572005A (en) 2018-03-16 2019-09-18 Univ Court Univ Of Edinburgh Macrophage-based therapy
CN112955161B (zh) * 2018-09-06 2024-12-17 泰克年研究发展基金会公司 通过活化细胞修复组织
GB202007905D0 (en) * 2020-05-27 2020-07-08 Univ Edinburgh Cryopressing macrophages
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
CN114622017A (zh) * 2020-12-14 2022-06-14 中山大学孙逸仙纪念医院 Isg15、isg15诱导的巨噬细胞及其分泌物在肿瘤治疗中的应用
WO2023075623A1 (en) * 2021-10-26 2023-05-04 Ineb (Instituto Nacional De Engenharia Biomédica) Macrophage phenoypes for use in the treatment of intravertebral discs
CN115212320B (zh) * 2022-08-04 2025-07-15 温州医科大学慈溪生物医药研究院 一种双靶向脂质体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103977029A (zh) 2014-04-11 2014-08-13 中国人民解放军第四军医大学 经典激活的巨噬细胞在治疗肝纤维化的应用
WO2016114723A1 (en) 2015-01-16 2016-07-21 Agency For Science, Technology And Research Differentiation of macrophages from pluripotent stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103977029A (zh) 2014-04-11 2014-08-13 中国人民解放军第四军医大学 经典激活的巨噬细胞在治疗肝纤维化的应用
WO2016114723A1 (en) 2015-01-16 2016-07-21 Agency For Science, Technology And Research Differentiation of macrophages from pluripotent stem cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Immunity,2010,Vol.32,p.593-604
J.Immunol.Methods,2012,Vol.385,p.1-14
J.Leukoc.Biol.,2008,Vol.84,p.1410-1421
Nat. Rev. Immunol., 2003, Vol. 3, p. 23-35

Also Published As

Publication number Publication date
EP3515460B1 (en) 2025-09-17
JP2019532634A (ja) 2019-11-14
US11285174B2 (en) 2022-03-29
CN109789163A (zh) 2019-05-21
WO2018051136A9 (en) 2019-02-07
AU2017328913A1 (en) 2019-02-28
AU2017328913B2 (en) 2023-08-17
EP4640237A2 (en) 2025-10-29
EP3515460A1 (en) 2019-07-31
US20190240256A1 (en) 2019-08-08
WO2018051136A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
JP7115755B2 (ja) 肝損傷の処置における使用のためのマクロファージに基づく治療法
King et al. Sphingosine-1-phosphate prevents egress of hematopoietic stem cells from liver to reduce fibrosis
Haideri et al. Injection of embryonic stem cell derived macrophages ameliorates fibrosis in a murine model of liver injury
Park et al. Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice
Liu et al. Transplanted endothelial progenitor cells ameliorate carbon tetrachloride–induced liver cirrhosis in rats
JP2013528230A (ja) ノーオプション重症虚血肢（ｃｌｉ）を処置するための組成物および方法
JP2023001294A (ja) 臓器線維症の予防または治療剤
CN107988141A (zh) 肝纤维化模型及其构建方法与应用
Danilova et al. Recruitment of macrophages and bone marrow stem cells to regenerating liver promoted by sodium phthalhydrazide in mice
Leng et al. Experimental study on the effect of allogeneic endothelial progenitor cells on wound healing in diabetic mice
JP4965000B2 (ja) 肝臓関連疾患治療薬
Jin et al. Hepatocyte growth factor promotes liver regeneration induced by transfusion of bone marrow mononuclear cells in a murine acute liver failure model
Gaowa et al. Recombinant soluble thrombomodulin accelerates epithelial stem cell proliferation in mouse intestinal organoids and promotes the mucosal healing in colitis
US20210128699A1 (en) Neutrophil activation regulator
CN107970435B (zh) 联合诱导内源Lgr5+肝脏干细胞增多的方法及应用
US20240189364A1 (en) Villi stromal cells compositions and uses thereof
CN107982518A (zh) 一种Lgr5阳性肝脏干细胞诱导方法及其检测应用
Cardona et al. Skin reaction is a significant predictor for favorable response to sorafenib in patients with hepatocellular carcinoma
Adé Kupffer Cell Maintenance in Tissue Repair and Ageing
Alfaifi Cell therapy for acute liver injury-in vivo efficacy of mesenchymal stromal cells in toxic and immune-mediated murine hepatitis
Norman Jr Origin and maturation of the pulmonary lymphatic endothelium
Ghita Adipose derived stromal vascular fraction: therapeutic potential of renal artery administration in renal ischaemia reperfusion injury
King et al. BASIC AND TRANSLATIONAL—LIVER
Mohamed et al. COMPARATIVE STUDY BETWEEN THE EFFECTS OF HUMAN CD34 AND RAT BONE MARROW MESENCHYMAL STEM CELLS ON AMELIORATION OF CCL4 INDUCED LIVER FIBROSIS.
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220721

R150 Certificate of patent or registration of utility model

Ref document number: 7115755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250